IL251848A0 - Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production - Google Patents

Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Info

Publication number
IL251848A0
IL251848A0 IL251848A IL25184817A IL251848A0 IL 251848 A0 IL251848 A0 IL 251848A0 IL 251848 A IL251848 A IL 251848A IL 25184817 A IL25184817 A IL 25184817A IL 251848 A0 IL251848 A0 IL 251848A0
Authority
IL
Israel
Prior art keywords
production
methods
dimeric immunoglobulins
cell retargeting
hetero
Prior art date
Application number
IL251848A
Other languages
Hebrew (he)
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/073738 external-priority patent/WO2015063339A1/en
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of IL251848A0 publication Critical patent/IL251848A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL251848A 2014-11-04 2017-04-23 Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production IL251848A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2014/073738 WO2015063339A1 (en) 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins
EP15167034 2015-05-08
PCT/EP2015/075628 WO2016071355A1 (en) 2014-11-04 2015-11-03 Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Publications (1)

Publication Number Publication Date
IL251848A0 true IL251848A0 (en) 2017-06-29

Family

ID=53059011

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251848A IL251848A0 (en) 2014-11-04 2017-04-23 Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Country Status (20)

Country Link
EP (1) EP3215541A1 (en)
JP (3) JP2018501297A (en)
KR (1) KR20170078831A (en)
CN (1) CN107207596A (en)
AU (1) AU2015341884B2 (en)
BR (1) BR112017009263A2 (en)
CA (1) CA2965745C (en)
CL (1) CL2017001090A1 (en)
CO (1) CO2017005240A2 (en)
EA (1) EA039658B1 (en)
HK (1) HK1244014A1 (en)
IL (1) IL251848A0 (en)
MA (1) MA40894A (en)
MX (1) MX2017005814A (en)
MY (1) MY186929A (en)
NZ (1) NZ732019A (en)
PE (1) PE20171041A1 (en)
PH (1) PH12017500819A1 (en)
SG (1) SG11201703313SA (en)
WO (1) WO2016071355A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2918795A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
KR20160090308A (en) 2013-11-04 2016-07-29 그렌마크 파머수티칼스 에스. 아. Production of t cell retargeting hetero-dimeric immunoglobulins
AP2016009475A0 (en) 2014-03-28 2016-09-30 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
ES2886523T3 (en) 2014-11-26 2021-12-20 Xencor Inc Heterodimeric antibodies that bind to CD3 and CD20
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
MX2019012606A (en) * 2017-04-24 2019-12-02 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers.
CN110691789A (en) 2017-06-05 2020-01-14 努玛治疗有限公司 Novel anti-CD 3 antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
WO2018224685A1 (en) * 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
US11780930B2 (en) 2017-06-08 2023-10-10 Black Belt Therapeutics Limited CD38 modulating antibody
BR112020002636A2 (en) * 2017-08-10 2020-07-28 Grifols Diagnostic Solutions Inc. compositions, methods and / or kits comprising a recombinant extracellular domain of human cd38
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
KR20200036861A (en) 2017-08-16 2020-04-07 블랙 벨트 테라퓨틱스 리미티드 CD38 antibody
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
US20220034899A1 (en) * 2018-09-25 2022-02-03 Ichnos Sciences S.A. Antibody quantification in biological samples
KR102353568B1 (en) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 Anti c-Met Antibody or Antigen binding fragment thereof with Improved Stability
AU2020211728A1 (en) 2019-01-23 2021-08-12 Encefa CD31 competitors and uses thereof
US20220177582A1 (en) * 2019-03-13 2022-06-09 Ichnos Sciences SA Non-consensus glycosylation of bispecific antibodies
BR112021023026A2 (en) * 2019-05-23 2022-01-04 Velosbio Inc Bispecific anti-ror1/anti-cd3 binding molecules
JPWO2020250940A1 (en) * 2019-06-11 2020-12-17
CN110551222B (en) * 2019-08-27 2023-06-06 重庆市畜牧科学院 Novel bifunctional antibody and application thereof
WO2021063330A1 (en) * 2019-09-30 2021-04-08 和铂医药(苏州)有限公司 Cd3-targeting antibody, bispecific antibody and use thereof
CN113493519B (en) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 Fusion protein with remarkably prolonged half-life for treating ocular angiogenesis diseases
JP2023523584A (en) * 2020-04-24 2023-06-06 メモリアル スローン ケタリング キャンサー センター Anti-CD3 antibody and use thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4168450A2 (en) * 2020-06-17 2023-04-26 Y-Mabs Therapeutics, Inc. Cd38 antibodies for the treatment of human diseases
KR20230166150A (en) 2020-08-19 2023-12-06 젠코어 인코포레이티드 Anti-cd28 compositions
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2915820A1 (en) * 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
IL296666A (en) * 2005-03-23 2022-11-01 Genmab As Antibodies against cd38 for treatment of multiple myeloma
CN106434683B (en) * 2005-10-12 2020-03-13 莫佛塞斯公司 Generation and characterization of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN103833855A (en) * 2009-06-26 2014-06-04 瑞泽恩制药公司 Readily isolated bispecific antibodies with native immunoglobulin format
BR112012017124C1 (en) * 2009-12-25 2021-08-31 Chugai Pharmaceutical Co Ltd Method for making and purifying a polypeptide multimer
DK2580243T3 (en) * 2010-06-09 2020-01-13 Genmab As ANTIBODIES AGAINST HUMAN CD38
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
CN107840894A (en) * 2011-03-25 2018-03-27 格兰马克药品股份有限公司 Heterodimer immunoglobulin
AU2013322710A1 (en) * 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
ES2621377T3 (en) * 2012-11-05 2017-07-03 Morphosys Ag Radiolabelled antibody and uses thereof
KR20160090308A (en) * 2013-11-04 2016-07-29 그렌마크 파머수티칼스 에스. 아. Production of t cell retargeting hetero-dimeric immunoglobulins

Also Published As

Publication number Publication date
CA2965745A1 (en) 2016-05-12
EA039658B1 (en) 2022-02-22
CO2017005240A2 (en) 2017-10-31
NZ732019A (en) 2022-07-29
EA201790961A1 (en) 2017-10-31
PE20171041A1 (en) 2017-07-19
AU2015341884B2 (en) 2020-09-17
JP2018501297A (en) 2018-01-18
HK1244014A1 (en) 2018-07-27
MA40894A (en) 2017-09-12
MX2017005814A (en) 2017-08-02
EP3215541A1 (en) 2017-09-13
KR20170078831A (en) 2017-07-07
PH12017500819A1 (en) 2017-10-02
CL2017001090A1 (en) 2018-01-05
CN107207596A (en) 2017-09-26
CA2965745C (en) 2023-12-05
MY186929A (en) 2021-08-26
WO2016071355A1 (en) 2016-05-12
JP2021184722A (en) 2021-12-09
JP7403505B2 (en) 2023-12-22
JP2019214582A (en) 2019-12-19
BR112017009263A2 (en) 2018-01-30
SG11201703313SA (en) 2017-05-30
AU2015341884A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
HK1244014A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
IL286835A (en) Bispecific tetravalent antibodies and methods of makiing and using thereof
HK1252413A1 (en) Method of culturing akkermansia
IL253149A0 (en) Methods of making chimeric antigen receptor-expressing cells
ZA201603433B (en) Production of t cell retargeting hetero-dimeric immunoglobulins
IL248007A0 (en) Bispecific antibodies that bind to cd38 and cd3
IL257411A (en) Enhanced production of immunoglobulins
HK1251969A1 (en) Anti-her2 antibodies and methods of use
SG11201606575TA (en) Method of producing polyethylene and polyethylene thereof
HK1251580B (en) Process of manufacture of annexin v
IL248697A0 (en) Methods of purifying antibodies
ZA201700525B (en) Method of synthetic fuel gas production
IL250451A0 (en) Anti-vasa antibodies, and methods of production and use thereof
PL3140392T3 (en) Production of heteromultimeric proteins using mammalian cells
GB201608060D0 (en) Method of culturing T cells
IL252712A0 (en) Method of protein manufacture
SG11201609269TA (en) Method of culturing cells
GB201411430D0 (en) Method of producing metallic tanralum
PT3194599T (en) Method for production of modified cells exprining hox and modified cells obtained by the method